
|Videos|May 7, 2021
Analyzing 24-month data of the PALADIN study
Author(s)David Hutton, OT Staff Reports
Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
Advertisement
Michael A. Singer, MD, of the Medical Center Ophthalmology Associates in San Antonio, Texas, speaks on the highlights of his presentation focusing on intraocular pressure (IOP) in the PALADIN 24-month data intravitreal steroid (ILUVIEN), presented during ARVO 2021.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
FDA approves NDA labeling supplement allowing re-administration of iDose TR
3
Opus Genetics launches phase 1/2 MERTK gene therapy trial
4
Dr. Mali’s top 5 predictions in ophthalmology for 2026
5



























